[CFRX] ContraFect Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 77.83 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.25 Change: 0.1 (4.65%)
Ext. hours: Change: 0 (0%)

chart CFRX

Refresh chart

Strongest Trends Summary For CFRX

CFRX is in the long-term up 23% in 2 years and down -65% below S&P in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding27.5 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV3.54 Price/Cash Per Share
Price/Free Cash Flow ROA-117.7% ROE-141.17% ROI
Current Ratio6.29 Quick Ratio Long Term Debt/Equity Debt Ratio0.17
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit-4.49 M Operating Profit-4.7 M Total Assets25.31 M Total Current Assets23.15 M
Total Current Liabilities3.68 M Total Debt Total Liabilities4.21 M Total Revenue
Technical Data
High 52 week2.82 Low 52 week0.9 Last close1.51 Last change-3.21%
RSI32.58 Average true range0.27 Beta0.65 Volume23.29 K
Simple moving average 20 days-27.09% Simple moving average 50 days-26.51% Simple moving average 200 days-23.58%
Performance Data
Performance Week-26.7% Performance Month-27.75% Performance Quart-7.93% Performance Half-42.8%
Performance Year52.53% Performance Year-to-date49.51% Volatility daily7.32% Volatility weekly16.36%
Volatility monthly33.54% Volatility yearly116.17% Relative Volume129.23% Average Volume258.19 K
New High New Low

News

2019-01-17 10:00:00 | Antimicrobials Working Group Announces Updates to Leadership Team

2019-01-17 09:26:00 | These 4 Healthcare Stocks Are Raising Expectations

2019-01-17 07:00:00 | ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program

2019-01-09 09:45:00 | CFRX: Exebacase Improves Clinical Outcomes in Phase 2 Trial…

2019-01-07 07:00:00 | ContraFect’s Exebacase CF-301 Improved Clinical Outcomes in Staphylococcus aureus Bacteremia including  Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study

2018-12-23 10:22:03 | Is ContraFect Corp CFRX A Good Stock To Buy?

2018-12-20 17:00:00 | ContraFect to Present at Biotech Showcase 2019

2018-11-19 07:00:00 | ContraFect to Present at Piper Jaffray Health Care Conference

2018-11-16 07:50:00 | Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals — Discovering Underlying Factors of Influence

2018-11-12 09:15:00 | CFRX: Waiting on Data from Phase 2 Study of CF-301…

2018-11-12 07:00:00 | ContraFect Appoints Michael Messinger as Chief Financial Officer

2018-11-08 09:59:21 | ContraFect: 3Q Earnings Snapshot

2018-11-08 07:00:00 | ContraFect Announces Third Quarter 2018 Financial Results

2018-11-01 07:00:00 | ContraFect to Present at 2nd International Symposium on Antimicrobial Hydrolytic Enzymes

2018-10-22 17:00:00 | ContraFect to Participate in World Antimicrobial Resistance Congress 2018

2018-09-25 07:00:00 | ContraFect to Present at the “Exploring the Antibiotic Pipeline 2018” Symposium and also to Present New Data on CF-301 exebacase at IDWeek 2018

2018-09-24 09:30:00 | CFRX: Enrollment for Phase 2 Trial of CF-301 Complete; Data in 4Q18…

2018-09-20 17:00:00 | ContraFect to Present at Two Upcoming Investor Conferences

2018-09-06 08:30:00 | ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 exebacase in Patients with Staphylococcus Aureus Bacteremia

2018-08-29 17:30:00 | ContraFect to Present at Two Upcoming Investor Conferences

2018-08-14 17:00:00 | ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections

2018-08-13 12:15:00 | CFRX: Data from Phase 2 Trial of CF-301 in 4Q18…

2018-08-09 07:35:44 | ContraFect: 2Q Earnings Snapshot

2018-08-09 07:00:00 | ContraFect Announces Second Quarter 2018 Financial Results

2018-07-27 09:00:00 | ContraFect Corporation Prices $10 Million Public Offering of Common Stock

2018-07-26 16:12:19 | ContraFect Corporation Announces Proposed Public Offering of Common Stock

2018-06-18 10:00:00 | CFRX: Developing Gram-Negative Lysin Targeting P. aeruginosa

2018-06-14 07:00:00 | ContraFect to Present at JMP Securities Life Sciences Conference

2018-06-06 10:08:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

2018-06-05 16:47:58 | Lysins plus antibiotics: A cure for human bacterial infections?

2018-06-01 21:17:00 | Glancy Prongay & Murray LLP Continues Investigation on Behalf of ContraFect Corporation Investors CFRX

2018-05-30 07:00:00 | ContraFect to Present New Data on CF-301 exebacase and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018

2018-05-14 11:50:00 | CFRX: Multiple Presentations on CF-301 at ECCMID

2018-05-10 07:58:31 | ContraFect: 1Q Earnings Snapshot

2018-05-10 07:00:00 | ContraFect Announces First Quarter 2018 Financial Results

2018-04-20 10:17:00 | Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2018-04-11 09:00:00 | ContraFect to Present CF-301 Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2018-03-27 15:04:00 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of ContraFect Corporation Investors CFRX

2018-03-27 07:00:00 | Free Post Earnings Research Report: Incyte’s Quarterly Sales 36% Surged

2018-03-21 11:30:00 | CFRX: No Safety Issues Noted Thus Far in Phase 2 Trial of CF-301

2018-03-15 08:01:51 | ContraFect reports 4Q loss

2018-03-15 07:00:00 | ContraFect Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

2018-03-14 07:00:00 | ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference

2018-01-11 07:00:00 | ContraFect to Present at Cantor Antibiotics Summit

2018-01-03 07:00:00 | ContraFect to Present at 10th Annual Biotech Showcase

2017-11-27 14:00:00 | CFRX: Additional Data on CF-301 Presented at ID Week 2017

2017-11-15 07:00:00 | ContraFect to Present at the 29th Annual Piper Jaffray Healthcare Conference

2017-11-10 07:00:00 | ContraFect to Present at the 2nd Annual Superdrugs and Superbugs USA Conference

2017-11-09 10:00:48 | ContraFect reports 3Q loss

2017-11-09 07:00:00 | ContraFect Announces Third Quarter 2017 Financial Results